Yanxia Shi

2.7k total citations · 1 hit paper
76 papers, 982 citations indexed

About

Yanxia Shi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Yanxia Shi has authored 76 papers receiving a total of 982 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 21 papers in Cancer Research. Recurrent topics in Yanxia Shi's work include Cancer Treatment and Pharmacology (21 papers), Advanced Breast Cancer Therapies (19 papers) and HER2/EGFR in Cancer Research (18 papers). Yanxia Shi is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), Advanced Breast Cancer Therapies (19 papers) and HER2/EGFR in Cancer Research (18 papers). Yanxia Shi collaborates with scholars based in China, United States and United Kingdom. Yanxia Shi's co-authors include Zhongyu Yuan, Shusen Wang, Xin An, Roujun Peng, Tao Qin, Fei Xu, Cong Xue, Yuchen Cai, Qiufan Zheng and Wen Xia and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Yanxia Shi

68 papers receiving 972 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

2020 192 citations Yanxia Shi, Jun Guo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yanxia Shi China	18	571	311	256	213	193	76	982
Ernesto Wasserman United States	17	812 1.4×	418 1.3×	358 1.4×	377 1.8×	141 0.7×	35	1.2k
A. Craig Lockhart United States	17	477 0.8×	522 1.7×	261 1.0×	234 1.1×	102 0.5×	49	1.0k
Jiuda Zhao China	17	764 1.3×	337 1.1×	573 2.2×	274 1.3×	214 1.1×	88	1.3k
Takafumi Koyama Japan	19	447 0.8×	293 0.9×	168 0.7×	144 0.7×	80 0.4×	87	871
Weikai Xiao China	18	477 0.8×	425 1.4×	265 1.0×	473 2.2×	114 0.6×	37	1.1k
Matthias Choschzick Germany	24	480 0.8×	396 1.3×	242 0.9×	250 1.2×	441 2.3×	51	1.4k
Annelies Debucquoy Belgium	20	677 1.2×	259 0.8×	162 0.6×	188 0.9×	266 1.4×	37	1.0k
Armando Orlandi Italy	17	519 0.9×	192 0.6×	248 1.0×	248 1.2×	124 0.6×	90	879
Joyce Cheng United States	13	596 1.0×	244 0.8×	370 1.4×	229 1.1×	62 0.3×	31	943
Reena Philip United States	16	583 1.0×	402 1.3×	302 1.2×	293 1.4×	80 0.4×	23	1.1k

Countries citing papers authored by Yanxia Shi

Since Specialization

Citations

This map shows the geographic impact of Yanxia Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanxia Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanxia Shi more than expected).

Fields of papers citing papers by Yanxia Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanxia Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanxia Shi. The network helps show where Yanxia Shi may publish in the future.

Co-authorship network of co-authors of Yanxia Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Yanxia Shi. A scholar is included among the top collaborators of Yanxia Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanxia Shi. Yanxia Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xue, Cong, Wei Yang, Anqi Hu, et al.. (2025). CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer. BMC Cancer. 25(1). 410–410. 1 indexed citations

Dun, S.L., Qifeng Zhou, Wen Xia, et al.. (2025). Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer. npj Breast Cancer. 11(1). 123–123.

Li, Siming, Yanxia Shi, Haiying Dong, et al.. (2024). Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China. Cancer Medicine. 13(21). e70368–e70368. 4 indexed citations

Chen, Meiting, et al.. (2024). Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance. The Oncologist. 29(8). e957–e966. 22 indexed citations

Zheng, Yabing, Wen‐Ming Cao, Xiying Shao, et al.. (2023). Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. Nature Communications. 14(1). 8314–8314. 10 indexed citations

Jiang, Kuikui, Ruoxi Hong, Qianyi Lu, et al.. (2023). Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study. Cancer Research and Treatment. 56(2). 513–521. 2 indexed citations

Duan, Fangfang, Chenge Song, Jiajia Huang, et al.. (2022). Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study. Journal of Oncology. 2022. 1–10. 1 indexed citations

Hong, Ruoxi, Wen Xia, Liye Wang, et al.. (2021). Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study. Cancer Communications. 41(2). 171–182. 23 indexed citations

Chou, Ping‐Chieh, Hyun Ho Choi, Yizhi Huang, et al.. (2021). Impact of diabetes on promoting the growth of breast cancer. Cancer Communications. 41(5). 414–431. 17 indexed citations

10.

Ma, Jun, Huiqiang Huang, Peifen Fu, et al.. (2021). Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Annals of Translational Medicine. 9(10). 893–893. 2 indexed citations

11.

Lu, Qianyi, Fei Xu, Wen Xia, et al.. (2020). Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center. Cancer Communications. 40(5). 222–233. 15 indexed citations

12.

Wang, Xinyue, Jibin Li, Wei Shi, et al.. (2020). Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. The Oncologist. 25(10). e1439–e1445. 5 indexed citations

13.

Jiang, Kuikui, Wen Xia, Ruoxi Hong, et al.. (2020). Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy. Translational Cancer Research. 9(2). 1225–1234. 3 indexed citations

14.

Zhang, Kai, Ruoxi Hong, Fei Xu, et al.. (2019). CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. Cancer Letters. 447. 130–140. 35 indexed citations

15.

Xue, Cong, Wenwen Wei, Peng Sun, et al.. (2018). Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment. 173(3). 619–628. 10 indexed citations

16.

Yang, Benlong, J.-H Chou, Xinhong Wu, et al.. (2018). An assessment of prognostic immunity markers in breast cancer. npj Breast Cancer. 4(1). 35–35. 30 indexed citations

17.

Shi, Yanxia, Ye Cao, Jianan Wang, et al.. (2016). Integrative Comparison of mRNA Expression Patterns in Breast Cancers from Caucasian and Asian Americans with Implications for Precision Medicine. Cancer Research. 77(2). 423–433. 18 indexed citations

18.

Xia, Qing, Yuchen Cai, Roujun Peng, et al.. (2013). The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition. International Journal of Oncology. 44(3). 735–744. 49 indexed citations

19.

Shi, Yanxia, Yuting Tan, Zhongyu Yuan, et al.. (2011). Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. Medical Oncology. 29(1). 39–47. 5 indexed citations

20.

He, Jiehua, Zhongyu Yuan, Shusen Wang, et al.. (2011). EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Medical Oncology. 29(2). 401–405. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact